ImmuCell Corporation Net Income (Loss) Attributable to Noncontrolling Interest
ImmuCell Corporation (ICCC) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$1.38 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2023-08-10
- ImmuCell Corporation net income (loss) attributable to noncontrolling interest for the quarter ending 2023-06-30 was -$1.38M.
- ImmuCell Corporation net income (loss) attributable to noncontrolling interest for the quarter ending 2023-03-31 was -$2.32M, a 551.03% decline year-over-year.
- ImmuCell Corporation net income (loss) attributable to noncontrolling interest for the quarter ending 2022-12-31 was -$1.67M, a 2349.80% decline year-over-year.
- ImmuCell Corporation net income (loss) attributable to noncontrolling interest for the quarter ending 2022-09-30 was -$655.08K, a 543.33% decline year-over-year.
- ImmuCell Corporation net income (loss) attributable to noncontrolling interest for fiscal 2022 was -$2.49M.
- ImmuCell Corporation net income (loss) attributable to noncontrolling interest for fiscal 2021 was -$78.29K.
- ImmuCell Corporation net income (loss) attributable to noncontrolling interest for fiscal 2020 was -$1.02M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|
| 2023-06-30 | -$1.38M 10-Q · filed 2023-08-10 | -$3.69M 10-Q · filed 2023-08-10 | -$5.36M derived: sum of 3 quarters · filed 2023-08-10 | -$6.02M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2023-03-31 | -$2.32M 10-Q · filed 2023-05-11 | -$3.98M derived: sum of 2 quarters · filed 2023-05-11 | -$4.64M derived: sum of 3 quarters · filed 2023-05-11 | -$5.32M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-12-31 | -$1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$2.32M derived: sum of 2 quarters · filed 2023-03-29 | -$3.01M derived: sum of 3 quarters · filed 2023-08-10 | -$2.49M 10-K · filed 2023-03-29 | ||
| 2022-09-30 | -$655.08K 10-Q · filed 2022-11-21 | -$1.34M derived: sum of 2 quarters · filed 2023-08-10 | -$825.94K 10-Q · filed 2022-11-21 | -$751.80K derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-06-30 | -$684.15K 10-Q · filed 2023-08-10 | -$170.86K 10-Q · filed 2023-08-10 | $51.52K 10-Q · filed 2022-08-11 | -$96.73K derived: sum of 3 quarters · filed 2023-08-10 | $51.04K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $513.29K 10-Q · filed 2023-05-11 | $735.67K 10-Q · filed 2022-05-12 | $587.42K derived: sum of 2 quarters · filed 2023-05-11 | $735.18K derived: sum of 3 quarters · filed 2023-05-11 | $876.30K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $74.13K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $221.90K derived: sum of 2 quarters · filed 2023-03-29 | $363.01K derived: sum of 3 quarters · filed 2023-03-29 | -$78.29K 10-K · filed 2023-03-29 | ||
| 2021-09-30 | $147.76K 10-Q · filed 2022-11-21 | $288.88K derived: sum of 2 quarters · filed 2022-11-21 | -$152.43K 10-Q · filed 2022-11-21 | $36.40K derived: sum of 4 quarters · filed 2022-11-21 | ||
| 2021-06-30 | $141.11K 10-Q/A · filed 2022-11-21 | -$300.19K 10-Q/A · filed 2022-11-21 | -$111.36K derived: sum of 3 quarters · filed 2022-11-21 | -$434.25K derived: sum of 4 quarters · filed 2022-11-21 | ||
| 2021-03-31 | -$441.30K 10-Q/A · filed 2022-11-21 | -$252.47K derived: sum of 2 quarters · filed 2022-11-21 | -$575.36K derived: sum of 3 quarters · filed 2022-11-21 | -$1.34M derived: sum of 4 quarters · filed 2022-11-21 | ||
| 2020-12-31 | $188.83K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$134.06K derived: sum of 2 quarters · filed 2022-03-30 | -$899.85K derived: sum of 3 quarters · filed 2022-03-30 | -$1.02M 10-K · filed 2022-03-30 | ||
| 2020-09-30 | -$322.89K 10-Q · filed 2021-11-15 | -$1.09M derived: sum of 2 quarters · filed 2021-11-15 | -$1.21M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$765.79K 10-Q · filed 2021-08-12 | -$888.06K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |